CG Oncology (CGON) EPS (Weighted Average and Diluted) (2023 - 2025)
Historic EPS (Weighted Average and Diluted) for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$0.57.
- CG Oncology's EPS (Weighted Average and Diluted) fell 9000.0% to -$0.57 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.04, marking a year-over-year increase of 6229.21%. This contributed to the annual value of -$1.41 for FY2024, which is 9099.87% up from last year.
- According to the latest figures from Q3 2025, CG Oncology's EPS (Weighted Average and Diluted) is -$0.57, which was down 9000.0% from -$0.54 recorded in Q2 2025.
- In the past 5 years, CG Oncology's EPS (Weighted Average and Diluted) registered a high of -$0.28 during Q2 2024, and its lowest value of -$4.47 during Q4 2023.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$1.69, with a median of -$0.54 in 2025.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 9287.53% in 2024, then plummeted by 9285.71% in 2025.
- Over the past 3 years, CG Oncology's EPS (Weighted Average and Diluted) (Quarter) stood at -$4.47 in 2023, then skyrocketed by 88.62% to -$0.51 in 2024, then decreased by 12.03% to -$0.57 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.57 in Q3 2025, compared to -$0.54 in Q2 2025 and -$0.45 in Q1 2025.